Acute Coronary Syndrome Global Market Report 2024: Key Players, Demand Patterns And Forecasts 2033 | Pfizer Inc., Johnson and Johnson Limited, Siemens AG, F. Hoffmann-La Roche Ltd., Merck & Co. Inc

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Acute Coronary Syndrome Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The acute coronary syndrome market size has grown strongly in recent years. It will grow from $9.23 billion in 2023 to $9.86 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to public health initiatives, adoption of telemedicine and remote monitoring, improved emergency medical services, demand for patient education.

The acute coronary syndrome market size is expected to see strong growth in the next few years. It will grow to $12.44 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to demand for personalized medicine, increase in interventional cardiology, increasing awareness, global aging population. Major trends in the forecast period include advancements in diagnostic tools, integration of health information technology, rapid response systems, technological advancements.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=12985&type=smp

Market Segmentation:
The main types of acute coronary syndrome are non-st-elevation myocardial infarction, st-elevation myocardial infarction and unstable angina. Non-st-elevation myocardial infarction (NSTEMI) refers to a form of heart attack where one or more coronary arteries are partially or completely blocked, reducing blood supply to the heart muscle. The various treatment includes medications, statins, beta-blockers, ace inhibitors, anticoagulants and others for diagnosis includes stress tests, blood tests, imaging and others. The various route of administration includes oral and parenteral. These are used by various end-users such as hospitals, specialty clinics and others.

Major Driver - Rising Prevalence Of Chronic Diseases Fuels Growth In The Acute Coronary Syndrome Market
The increasing prevalence of chronic diseases such as coronary artery disease, ischemic heart disease and vascular diseases is expected to propel the growth of the acute coronary syndrome market going forward. Ischemic heart disease is a chronic disease caused by the obstruction or narrowing of the coronary arteries. The treatment of acute coronary syndrome (ACS) is aimed at promptly relieving symptoms, minimizing heart damage and preventing further complications for patients suffering from various acute coronary syndromes, including ischemic heart disease and vascular diseases. For instance, in August 2022, according to a study published in the Journal of the American College of Cardiology, a US-based organization, all four cardiovascular risk factors are anticipated to rise among the general U.S. population between 2025 and 2060, dyslipidemia increased by 27.6%, and hypertension by 25.1%. The researchers discovered that heart failure (33.4%) and ischemic heart disease (30.7%) had the biggest anticipated increases in rates, followed by heart attack (16.9%) and stroke (33.8%). Therefore, the prevalence of chronic diseases such as coronary artery disease, ischemic heart disease and vascular diseases drives the acute coronary syndrome market.

Competitive Landscape:
Major players in the acute coronary syndrome market are Pfizer Inc., Johnson and Johnson Limited, Siemens AG, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Stryker Corporation, GE Healthcare Inc., Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Terumo Corp., BioMérieux SA, Beckman Coulter Inc., Quidel Corporation, Bio-Rad Laboratories Inc., Biotronik Inc., Randox Laboratories Limited, Nihon Kohden Corporation, Trinity Biotech plc.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report

Top Trend - Innovative Drug Development Fuels Advancements In Acute Coronary Syndrome Treatment
Major companies operating in the acute coronary syndrome market are developing innovative drugs to treat acute coronary syndrome and sustain their position in the market. The advancements in drug development can increase the efficiency of ACS treatment, reducing the time and resources required for each patient. For instance, in June 2023, AGEPHA Pharma USA LLC, a US-based pharmaceutical company, launched Lodoco, which was approved by the Food and Drug Administration (FDA), a US-based government agency. This is the first anti-inflammatory atheroprotective cardiovascular treatment that reduces the risk of heart stroke, coronary revascularization, myocardial infarction (MI) and cardiovascular death in adult patients with cardiovascular diseases, including acute coronary syndrome.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Acute Coronary Syndrome Market Characteristics
3. Acute Coronary Syndrome Market Trends And Strategies
4. Acute Coronary Syndrome Market - Macro Economic Scenario
5. Acute Coronary Syndrome Market Size And Growth
…..
27. Acute Coronary Syndrome Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.